These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7169978)

  • 1. Role of the control of phosphate in the progression of chronic renal failure.
    Barrientos A; Arteaga J; Rodicio JL; Alvarez Ude F; Alcazar JM; Ruilope LM
    Miner Electrolyte Metab; 1982 Mar; 7(3):127-33. PubMed ID: 7169978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
    Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
    Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exogenous calcitonin protects against renal bone disease in rats with early renal failure.
    D'Angelo A; Bonucci E; Giannini S; Benetollo P; Lodetti MG; Castrignano R; Malvasi L; Maschio G
    Bone Miner; 1987 Nov; 3(2):171-6. PubMed ID: 3505198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of zero magnesium dialysate and magnesium supplements on ionised calcium concentration in patients on regular dialysis treatment.
    Breuer J; Moniz C; Baldwin D; Parsons V
    Nephrol Dial Transplant; 1987; 2(5):347-50. PubMed ID: 3122112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1-alpha-OH-cholecalciferol (1-alpha-OHD3) and low phosphate diet in predialysis chronic renal failure: effects on renal function and on secondary hyperparathyroidism.
    Coen G; Messa F; Massimetti C; Mazzaferro S; Manganiello M; Donato G; Finistauri D; Giuliano G; Cinotti GA
    Acta Vitaminol Enzymol; 1984; 6(2):129-35. PubMed ID: 6496255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Iatrogenic aluminum osteopathy in a uremic infant].
    Koch H; Reich H; Franke D; Delling G
    Monatsschr Kinderheilkd; 1986 May; 134(5):279-81. PubMed ID: 3724766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphate binders in hyperphosphatemia of chronic renal failure.
    Wasan SM; Godley PJ
    DICP; 1991 Sep; 25(9):942-5. PubMed ID: 1949972
    [No Abstract]   [Full Text] [Related]  

  • 10. RenaGel efficacy in severe secondary hyperparathyroidism.
    Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
    Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of lowering the serum phosphate on parathyroid hormone secretion and total serum calcium during regular hemodialysis.
    Hill AV; Thein-Than ; Cook DB; Derr KN; Latner AL
    Clin Nephrol; 1973; 1(5):284-9. PubMed ID: 4797465
    [No Abstract]   [Full Text] [Related]  

  • 12. Calcium carbonate as an alternative to aluminium hydroxide in maintenance haemodialysis for chronic renal failure.
    O'Brien A; McParland C; Keogh B
    Ir Med J; 1987 Feb; 80(2):68-70. PubMed ID: 3557928
    [No Abstract]   [Full Text] [Related]  

  • 13. [Methods of correcting hyperphosphatemia in chronic renal failure and in dialysis (review)].
    Novikov AI
    Ter Arkh; 1997; 69(12):63-7. PubMed ID: 9503540
    [No Abstract]   [Full Text] [Related]  

  • 14. Detrimental effect of hypophosphatemia on the severity and progression of ischemic acute renal failure.
    Lumlertgul D; Harris DC; Burke TJ; Schrier RW
    Miner Electrolyte Metab; 1986; 12(3):204-9. PubMed ID: 3724706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
    Siu YP; Leung KT; Tong MK; Kwan TH
    Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a phosphate management protocol to achieve optimum serum phosphate levels in hemodialysis patients.
    Yokum D; Glass G; Cheung CF; Cunningham J; Fan S; Madden AM
    J Ren Nutr; 2008 Nov; 18(6):521-9. PubMed ID: 18940656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salivary phosphate secretion in chronic kidney disease.
    Savica V; Calò L; Santoro D; Monardo P; Granata A; Bellinghieri G
    J Ren Nutr; 2008 Jan; 18(1):87-90. PubMed ID: 18089451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcium salts of keto-amino acids, a phosphate binder alternative for patients on CAPD.
    Macia M; Coronel F; Navarro JF; Gallego E; Herrero JA; Méndez ML; Chahin J; García J
    Clin Nephrol; 1997 Sep; 48(3):181-4. PubMed ID: 9342490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of significant circadian and post-prandial variation in phosphate levels in subjects receiving chronic hemodialysis therapy.
    Trivedi H; Moore H; Atalla J
    J Nephrol; 2005; 18(4):417-22. PubMed ID: 16245246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of a keto acid supplement on the course of chronic renal failure and nutritional parameters in predialysis patients and patients on regular hemodialysis therapy: the Hungarian Ketosteril Cohort Study.
    Zakar G;
    Wien Klin Wochenschr; 2001 Sep; 113(17-18):688-94. PubMed ID: 11603104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.